223 related articles for article (PubMed ID: 33095670)
21. Acute and Late Toxicity after Moderate Hypofractionation with Simultaneous Integrated Boost (SIB) Radiation Therapy for Prostate Cancer. A Single Institution, Prospective Study.
Jorgo K; Polgar C; Major T; Stelczer G; Herein A; Pocza T; Gesztesi L; Agoston P
Pathol Oncol Res; 2020 Apr; 26(2):905-912. PubMed ID: 30888646
[TBL] [Abstract][Full Text] [Related]
22. Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial.
Kishan AU; Ma TM; Lamb JM; Casado M; Wilhalme H; Low DA; Sheng K; Sharma S; Nickols NG; Pham J; Yang Y; Gao Y; Neylon J; Basehart V; Cao M; Steinberg ML
JAMA Oncol; 2023 Mar; 9(3):365-373. PubMed ID: 36633877
[TBL] [Abstract][Full Text] [Related]
23. Stereotactic MRI-guided radiation therapy for localized prostate cancer (SMILE): a prospective, multicentric phase-II-trial.
Ristau J; Hörner-Rieber J; Buchele C; Klüter S; Jäkel C; Baumann L; Andratschke N; Garcia Schüler H; Guckenberger M; Li M; Niyazi M; Belka C; Herfarth K; Debus J; Koerber SA
Radiat Oncol; 2022 Apr; 17(1):75. PubMed ID: 35428327
[TBL] [Abstract][Full Text] [Related]
24. Linac-based stereotactic body radiation therapy for low and intermediate-risk prostate cancer : Long-term results and factors predictive for outcome and toxicity.
Franzese C; Badalamenti M; Di Brina L; D'Agostino G; Franceschini D; Comito T; Clerici E; Navarria P; Reggiori G; Mancosu P; Tomatis S; Scorsetti M
Strahlenther Onkol; 2020 Jul; 196(7):608-616. PubMed ID: 32303782
[TBL] [Abstract][Full Text] [Related]
25. Clinical outcomes of whole pelvis radiotherapy and stereotactic body radiotherapy boost for intermediate- and high-risk prostate cancer.
Kim HJ; Phak JH; Kim WC
Asia Pac J Clin Oncol; 2017 Oct; 13(5):e342-e347. PubMed ID: 26846353
[TBL] [Abstract][Full Text] [Related]
26. Safety of accelerated hypofractionated whole pelvis radiation therapy prior to high dose rate brachytherapy or stereotactic body radiation therapy prostate boost.
Phuong C; Chan JW; Ni L; Wall P; Mohamad O; Wong AC; Hsu IC; Chang AJ
Radiat Oncol; 2022 Jan; 17(1):12. PubMed ID: 35057827
[TBL] [Abstract][Full Text] [Related]
27. Magnetic resonance guided SBRT reirradiation in locally recurrent prostate cancer: a multicentric retrospective analysis.
Boldrini L; Romano A; Chiloiro G; Corradini S; De Luca V; Verusio V; D'Aviero A; Castelluccia A; Alitto AR; Catucci F; Grimaldi G; Trapp C; Hörner-Rieber J; Marchesano D; Frascino V; Mattiucci GC; Valentini V; Gentile P; Gambacorta MA
Radiat Oncol; 2023 May; 18(1):84. PubMed ID: 37218005
[TBL] [Abstract][Full Text] [Related]
28. Stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer: toxicity profile and early oncologic outcomes.
Hwang ME; Mayeda M; Liz M; Goode-Marshall B; Gonzalez L; Elliston CD; Spina CS; Padilla OA; Wenske S; Deutsch I
Radiat Oncol; 2019 Aug; 14(1):136. PubMed ID: 31375119
[TBL] [Abstract][Full Text] [Related]
29. Extreme hypofractionated stereotactic radiotherapy for elderly prostate cancer patients: side effects preliminary analysis of a phase II trial.
Gregucci F; Carbonara R; Surgo A; Ciliberti MP; Curci D; Ciocia A; Branà L; Ludovico GM; Scarcia M; Portoghese F; Caliandro M; Ludovico E; Paulicelli E; Di Guglielmo FC; Bonaparte I; Fiorentino A
Radiol Med; 2023 Apr; 128(4):501-508. PubMed ID: 36952115
[TBL] [Abstract][Full Text] [Related]
30. A single-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy.
Bolzicco G; Favretto MS; Satariano N; Scremin E; Tambone C; Tasca A
BMC Urol; 2013 Oct; 13():49. PubMed ID: 24134138
[TBL] [Abstract][Full Text] [Related]
31. Linac-based versus MR-guided SBRT for localized prostate cancer: a comparative evaluation of acute tolerability.
Nicosia L; Mazzola R; Rigo M; Giaj-Levra N; Pastorello E; Ricchetti F; Vitale C; Figlia V; Cuccia F; Ruggieri R; Alongi F
Radiol Med; 2023 May; 128(5):612-618. PubMed ID: 37055672
[TBL] [Abstract][Full Text] [Related]
32. Treatment outcomes of postoperative ultra-hypofractionated stereotactic body radiotherapy in prostate cancer.
Ozyigit G; Onal C; Beduk Esen CS; Tilki B; Hurmuz P
Urol Oncol; 2023 May; 41(5):252.e1-252.e8. PubMed ID: 36631368
[TBL] [Abstract][Full Text] [Related]
33. Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm(3)).
Janowski E; Chen LN; Kim JS; Lei S; Suy S; Collins B; Lynch J; Dritschilo A; Collins S
Radiat Oncol; 2014 Nov; 9():241. PubMed ID: 25398516
[TBL] [Abstract][Full Text] [Related]
34. Moderate versus extreme hypofractionated radiotherapy: a toxicity comparative analysis in low- and favorable intermediate-risk prostate cancer patients.
Nicosia L; Mazzola R; Rigo M; Figlia V; Giaj-Levra N; Napoli G; Ricchetti F; Corradini S; Ruggieri R; Alongi F
J Cancer Res Clin Oncol; 2019 Oct; 145(10):2547-2554. PubMed ID: 31324979
[TBL] [Abstract][Full Text] [Related]
35. A Phase 1 Trial of Focal Salvage Stereotactic Body Radiation Therapy for Radiorecurrent Prostate Cancer.
Patel KR; Rydzewski NR; Schott E; Cooley-Zgela T; Ning H; Cheng J; Salerno K; Huang EP; Pinto PA; Lindenberg L; Mena E; Choyke P; Turkbey B; Citrin DE
Pract Radiat Oncol; 2023; 13(6):540-550. PubMed ID: 37442430
[TBL] [Abstract][Full Text] [Related]
36. Stereotactic Hypofractionated Accurate Radiotherapy of the Prostate (SHARP), 36.25 Gy in Five Fractions for Localized Disease: A Case Series Results from King Faisal Specialist Hospital, Saudi Arabia.
Hegazy MW; Mahmood R
Gulf J Oncolog; 2016 May; 1(21):12-6. PubMed ID: 27250882
[TBL] [Abstract][Full Text] [Related]
37. First Australian experience of treating localised prostate cancer patients with CyberKnife stereotactic radiotherapy: early PSA response, acute toxicity and quality of life.
Dixit A; Tang C; Bydder S; Kedda MA; Vosikova E; Bharat C; Gill S
J Med Radiat Sci; 2017 Sep; 64(3):180-187. PubMed ID: 28271639
[TBL] [Abstract][Full Text] [Related]
38. Time-Driven Activity-Based Costing of CT-Guided vs MR-Guided Prostate SBRT.
Parikh NR; Clark MA; Patel P; Kafka-Peterson K; Zaide L; Ma TM; Steinberg ML; Cao M; Raldow AC; Lamb J; Kishan AU
Appl Radiat Oncol; 2021 Sep; 10(3):33-40. PubMed ID: 34671700
[TBL] [Abstract][Full Text] [Related]
39. A Phase II trial of arc-based hypofractionated intensity-modulated radiotherapy in localized prostate cancer.
Lock M; Best L; Wong E; Bauman G; D'Souza D; Venkatesan V; Sexton T; Ahmad B; Izawa J; Rodrigues G
Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1306-15. PubMed ID: 20708855
[TBL] [Abstract][Full Text] [Related]
40. Hypofractionated Radiation Therapy to the Prostate Bed With Intensity-Modulated Radiation Therapy (IMRT): A Phase 2 Trial.
Leite ETT; Ramos CCA; Ribeiro VAB; Salvajoli BP; Nahas WC; Salvajoli JV; Ynoe Moraes F
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1263-1270. PubMed ID: 33346091
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]